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Abstract 
 
Background and Aims 
 
Acetic acid chromoendoscopy (AAC) enhances the ability to correctly identify Barrett’s neoplasia 
and is increasingly used by both expert and non-expert endoscopists. Despite its increasing use, 
there is no validated training strategy to achieve competence. The aims of our study were to; 
develop a validated training tool in AAC-assisted lesion recognition, assess endoscopists baseline 
knowledge of AAC-assisted lesion recognition and evaluate the efficacy and impact of this training 
tool. 
 
Methods 
 
A validated assessment of 40 images and 20 videos was developed. 13 endoscopists with experience 
of Barrett’s endoscopy but no formal training in AAC were recruited into the study. Participants 
underwent: baseline assessment (1)online trainingassessment (2) interactive 
seminarassessment (3). 
 
Results 
 
Baseline assessment demonstrated a sensitivity of 83% and negative predictive value (NPV) 83%. 
Our online training intervention significantly improved sensitivity to 95% and NPV to 94% (p<0.01). 
Further improvement was seen with a one-day interactive seminar with live cases, increasing 
sensitivity to 98% and NPV to 97%.  
 
  
 Conclusions 
 
Our data demonstrate the need for training in AAC-assisted lesion recognition as baseline 
performance, even by Barrett’s experts, was poor. We were successful in developing and validating 
an online training and testing tool for AAC for Barrett’s neoplasia. Training intervention with our 
tool improves performance of endoscopists to meet ASGE PIVI standards. The training tool increases 
the endoscopist’s degree of confidence in the use of AAC. The training tool also leads to shift in 
attitudes of endoscopists from Seattle protocol towards AAC guided biopsy protocol for Barrett’s 
surveillance. 
  
 Barrett’s esophagus (BE) carries a risk of cancer 30-150 times greater than that for an age-matched 
population without BE [1]. Five-year-survival rates following the diagnosis of esophageal cancer are 
less than 15 percent [2]. The annual rate of transformation into esophageal adenocarcinoma (EAC) 
in patient’s with non-dysplastic BE is estimated to be between 0.07% to 0.82% [3,4].  However, the 
annual rate of progression from low-grade dysplasia (LGD) to high-grade dysplasia (HGD) or EAC is 
as high as 6.5%[5–7] and from HGD to EAC is 12-40% [8–10]. Detecting and treating dysplasia is the 
only way to prevent cancer developing. Current British Society of Gastroenterology (BSG) guidelines 
[11] recommend 2-to-5 yearly surveillance endoscopy with quadrantic, 2cm biopsies. This approach 
is recommended as dysplasia in Barrett’s is often flat, patchy and difficult to detect, with only 13% 
of lesions appearing as visible nodules[12]. These Seattle protocol biopsies may miss up to 40% of 
treatable cancers [13]. It is well-recognised that the protocol is poorly adhered to with studies 
reporting only 51% of patients receiving the appropriate number of biopsies; the longer the length 
of Barrett’s the worse the adherence [14,15]. 
 
To redress these limitations, a number of approaches have been suggested for visualising the 
neoplastic areas, enabling targeted-biopsy, including; dye sprays [16,17] and electronic imaging 
enhancement, such as tri-modal imaging [18–20]. Acetic acid (AA) is a weak fatty-acid that, when 
sprayed on Barrett’s mucosa, highlights surface patterns and causes an acetowhitening reaction 
(Figure 1 and Video 1)[21]. Dysplastic areas lose the acetowhitening effect faster than non-
dysplastic areas[22], highlighting areas for targeted-biopsy (Figure 2 and Video 2). This process is 
reversible and causes no damage to tissues. Two large cohort studies have demonstrated the 
effectiveness of AA in dysplasia detection in high-risk populations [23,24], demonstrating 
sensitivities for dysplasia detection of 90-95% and specificities 75-85%. Further work from the same 
groups have suggested that the number of biopsies needed to detect neoplasia could be significantly 
reduced if AA-targeted biopsies were used in place of Seattle protocol biopsies, reducing pathology 
related costs by 97% [25]. Tholoor et al. [26] reported the use of AA in a surveillance population, 
demonstrating a six-fold increase in neoplasia detection as compared to Seattle protocol biopsies, 
with a fifteen-fold decrease in the number of biopsies required. Pohl et al.[24] demonstrated in their 
large cohort study that the number of AA-targeted biopsies required to yield one diagnosis of 
dysplasia is 5.2, as compared to 228 mapping biopsies.  
The ASGE recently published key performance indicators for targeted-biopsies in Barrett’s 
neoplasia, suggesting cut offs for sensitivity of ≥90%, negative predictive value ≥98% and specificity 
of 80% [27]. Current published literature is suggestive that AA meets these criteria. However, the 
 accuracy of acetic acid chromoendoscopy (AAC) has only been reported by experts in tertiary 
centres. Prior to widespread uptake of this technique clinicians will need to be trained to achieve 
acceptable accuracy, sensitivity and specificity.  
 
This study reports on the development and validation of a training programme for AAC-assisted 
lesion recognition by means of an online training module, incorporating still-images and dynamic 
moving videos, as well as an interactive seminar including observed live procedures. Diagnostic 
performance and inter-observer agreement for each stage of training was assessed. 
 
Methods 
 
This was a prospective, educational evaluation study conducted at a tertiary referral centre for BE 
between March and April 2015. The study was approved by the National Health Service (NHS) 
Research Ethics Committee, reference number REC 15/SC/0085. The primary aim of this study was 
to develop and validate a training and assessment programme for AAC. The primary endpoints were 
to determine the construct validity of the image and video-based test (i.e. that the test appropriately 
differentiates between experts and non-experts) and determine the content validity of the training 
module for each stage of training. 
 
 
Module development 
 
A literature review was performed to identify key features of AAC in Barrett’s.  Based on this a novel 
AA classification was developed and validated[28] and learning objectives for the training 
programme identified. To meet these objectives an online training module was developed using the 
Moodle platform (Moodle Pty Ltd, Perth, Australia), hosted by the University of Portsmouth. The 
online platform was split into 7 chapters: 
 
1) Background and rationale behind AA use 
2) Validated AA classification: 
a. Focal early loss of acetowhitening (LAW): Yes/No 
b. Surface pattern: 
i. Large uniformly distributed pits (normal pit density) OR 
 ii. Compactly packed pits, smaller than surrounding mucosa (increased pit 
density) OR 
iii. Focal irregularity or disorganised pits 
iv. Absent surface pattern 
3) Lesion morphology: nodular/flat/depressed 
4) Benign Barrett’s examples: images and videos 
5) Dysplastic Barrett’s examples: images and videos 
6) Intramucosal cancer examples: images and videos 
7) In training quiz using both images and videos with direct feedback on answers. 
 
High definition (HD) still-images and videos of Barrett’s 2.5% AAC with corresponding histology were 
sourced from an established library of over 500 procedures. Images and videos were selected and 
reviewed by research fellows (FC, KK) for quality and visibility of the key features of AAC. Images 
and videos used for training were not repeated in the assessment. Videos were edited to 
demonstrate the Barrett’s segment in HD white light and following application of AA. Biopsies were 
not included in videos to avoid bias. Images were taken from video-clips and stored in portable 
network graphic (PNG) format, videos were edited in MP4 format and deliberately did not overtly 
focus on areas of abnormality. 
 
40 still-images (21 benign, 19 neoplasia) and 20 videos (10 benign, 10 neoplasia) were chosen for 
the assessment tool, totalling 60 individual cases. Although the majority of patients have non-
dysplastic BE, a heterogeneous mix of dysplastic and non-dysplastic cases was required to obtain 
unbiased accuracy rates. Only cases of HGD and intramucosal cancer (IMC) were used, as invasive 
cancer is generally obvious. The training module consisted of 8 images (4 benign and 4 neoplastic) 
and 9 videos (3 benign and 6 neoplastic). Images and videos were annotated to describe the key-
features of AAC-assisted lesion recognition. Included within the training module was a sample quiz 
of 8 questions providing immediate feedback (Figure 3), with a clear explanation of the diagnosis 
focusing on surface pattern, LAW reaction and morphology. Endoscopists were unable to access the 
training module without first completing the baseline assessment. The training module could be 
repeated as many times as the participant wished. Participants were not required to complete the 
online training module and assessments in one session. Having completed the training module, the 
same assessment exercise was immediately repeated without feedback on prior performance. 
 
 13 endoscopists took part in all stages of the study, all of whom were nationally certified, 
independent endoscopists with experience in Barrett’s endoscopy but no prior formal training in 
AAC-assisted lesion recognition. The group consisted of 5 consultant gastroenterologists, 2 
consultant upper GI surgeons and 6 nurse endoscopists (see Table 1). 
 
All were required to complete the training module prior to attending the live-interactive workshop 
held at Queen Alexandra Hospital on 24th April 2015. A state-of-the-art lecture (PB) was given, 
reiterating the key features of AAC-assisted lesion recognition. 5 live-cases were performed with 
endoscopists observing via interactive video-link. Cases were carefully preselected to include 2 
cases of non-dysplastic Barrett’s, 2 cases of dysplastic Barrett’s and 1 case of IMC, affording the 
opportunity for endoscopists to question and discuss the techniques employed and view real-time 
application of AA. At the end of the interactive seminar endoscopists immediately repeated the 
same assessment exercise without feedback on performance. Figure 4 shows a flow diagram of our 
training interventions. 
 
Prior to undertaking the pre-training assessment, participants were asked to fill out a questionnaire 
regarding their confidence in the use of AAC, the same questionnaire was completed at the end of 
the training interventions. Along with confidence, participants were asked their views with regard 
to switching Barrett’s surveillance assessments from 4 quadrant biopsies to an AA-targeted 
technique. 
 
Validation of the assessment test 
 
Prior to use, the content of the assessment test was evaluated to ensure it differentiates between 
experts and novices in AAC-assisted lesion recognition.  Two experts in the use of AA (PB, GLW) not 
involved in the selection of the images and videos for the test module, completed the test to 
benchmark expert performance. To evaluate performance of the test for novices in the AAC, 3 
independent endoscopists (1 GI-fellow, 2 consultant gastroenterologists) completed the same test 
module. Neither the experts nor the novices were involved in the subsequent training exercise. 
 
  
 Statistical analysis 
 
To investigate the construct validity of the assessment test, we assumed sensitivity achieved by 
expert AA users was 90% and non-users 70%,  based on the validation exercise for the assessment 
test (Table 2a&b). For a chi-squared test using a 5% significance level, with 80% power and a baseline 
difference of 20%, 59 independent observations would need to be recorded. However, because the 
data are not truly independent (same images and videos shown to different observers) we assumed 
that double the number of observations would satisfy the power calculation.  
 
To examine the content validity of the training module a 10% improvement in sensitivity between 
pre- (70%) and post-training (80%) performance was deemed to be clinically relevant. For a chi-
squared test with 5% significance level and 80% power, and again assuming the data are not truly 
independent, at least 291 observations would be required. Again, because the data are not truly 
independent, we assumed 780 observations for each stage of assessment, from 13 observers, would 
more than satisfy the power calculation 
 
Sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV,) 
were calculated for each observer (n=13) at each timepoint, using histopathological diagnosis as the 
reference standard. All analysis was performed using these summary values. Confidence intervals 
were calculated to illustrate the uncertainty in the estimated values, and, the 2-sided, paired t-test 
was used to compare between timepoints. A p-value<0.05 was deemed to be significant. 
 
Interobserver agreement for images and videos was assessed using the multi-rater Fleiss kappa () 
statistic. A  value <0.2 was regarded as poor agreement, 0.21-0.40 fair agreement, 0.41-0.60 
moderate agreement, 0.61-0.80 substantial agreement, 0.81-1.00 almost perfect agreement. 
 
Analyses were performed using the SPSS statistical package, version 22 for Macintosh (IBM corp).  
 
  
 Results 
 
Validation of the assessment module 
 
 Outcomes of the assessment module validation exercise are shown in Table 2a&b. These results 
were used to power the number of participants required for the study. Overall there was a 
significant difference in performance of experts and novices in both images and video-based 
assessment. Agreement between experts was extremely high and between novices fair.  
 
RESULTS OF TRAINING  
 
Intervention 1: Online training 
 
13 participants consented to the study. Assessment images and videos were completed prior to the 
online training module, with outcomes shown in Table 3a&b. Following online training, the 
assessment tool was completed demonstrating poor baseline performance but a significant 
improvement in sensitivity and NPV following the online training module.  
 
Intervention 2: Interactive Seminar: dedicated lectures and live case demonstration 
 
Following completion of the interactive training day the assessment tool was repeated (Table 4a&b) 
showing a statistically significant improvement in sensitivity and NPV for videos and a trend for 
improvement for images.  
 
 
Comparison of outcomes: Image vs Video assessments 
 
Assessment by images is no different from assessment by videos (Table 4), suggesting still-images 
serve as a reliable surrogate of videos. 
 
Results overall showed improvement in performance after each intervention. The greatest 
improvement in performance occurred after online training. Additional clinically relevant 
improvements, in particular for NPV, were seen following the interactive training day.  
  
Subgroup analysis of Experienced (n>50 procedures) Acetic Acid Users versus Non-experienced 
Table 6 a&b shows a subgroup analysis comparing acetic acid users (n=6) those who had performed 
over 50 acetic acid procedures prior to study enrolment compared to those who had done fewer, 
acetic acid naïve (n=7). 
 
 
Confidence in technique 
 
Endoscopist confidence in the use of the AAC-technique increased throughout training with a mean 
pre-training confidence level of 2.5 (5-point scale) with a post-training confidence level of 3.9 
(p<0.001). Training increased the willingness of endoscopists to switch from a 2cm quadrantic 
biopsy protocol to an AA-targeted technique with a mean willingness pre-training of 2.6 (5-point 
scale) rising to 3.8 post-training (p<0.001). Confidence in in-vivo diagnosis for images also improved 
during training with mean number of diagnoses made with high confidence 41% pre training rising 
to 63% after the online training module (p<0.001). The same was true for videos with mean number 
of diagnoses made with high confidence pre-training 47% rising to 67% following the online training 
module (p<0.001). Following the interactive training day high-confidence responses rose from 63% 
to 72% for images (p=0.045) and remained at 67% for videos. 
 
 
 
Discussion 
 
This study demonstrates the development of a novel training module for AAC-assisted in-vivo 
diagnosis of Barrett’s neoplasia. We have demonstrated the feasibility of training in AAC by a well-
validated training module. The advantage of the online training platform is that endoscopists can 
complete training at their own convenience. On average the online module takes 3 hours to 
complete. Additional clinical benefit was demonstrated from the interactive training day which we 
believe is integral to achieving competence in AAC-assisted lesion recognition in BE. 
 
Participants included endoscopists from a variety of backgrounds all of whom demonstrated  
clinically relevant improvements in accuracy, sensitivity and NPV for the detection of Barrett’s 
 neoplasia with AAC. This demonstrates the validity, effectiveness and widespread applicability of 
this tool. The technique of AAC is very simple and can be performed by any endoscopist but our 
data shows that lesion recognition after AAC is not that easy and requires training. This is 
demonstrated by our baseline assessment data which showed poor performance (pre-training) 
from both very experienced and inexperienced Barrett’s endoscopists, justifying the need and role 
of our training tool.  
 
There were significant improvements in the interobserver agreement following training with 
substantial agreement achieved by the end of training. This is important as previous studies [29] 
have demonstrated low interobserver agreement of non-experts without training in AAC. Clearly, 
with training interobserver agreement improves. 
 
This study demonstrates that the technique of in-vivo diagnosis for Barrett’s neoplasia using AA can 
be taught using images and videos. However, it appears that endoscopists find it harder to diagnose 
neoplasia from videos as opposed to still-images. This can be explained as static images have been 
pre-selected to focus on neoplasia, whereas videos focus on the entire Barrett’s segment, requiring 
more complex interpretation. Video performance improves following training. Sensitivity and NPV 
improved significantly following the interactive seminar but accuracy and specificity decreased. This 
can be explained by a higher number of false positives making AA safer – reducing the risk of missed 
neoplasia. At the end of the training exercise the sensitivity was 98% and 99% for images and videos 
respectively which is well above the ≥90% required by the ASGE PIVI criteria28. The same is true for 
NPV with mean scores of 97% and 98% for images and videos respectively again reaching the ASGE 
PIVI criteria28 of ≥98%. We believe that it is high NPV which is most critical, as this suggests that the 
neoplasia miss-rate is minimal, highlighting the safety of the technique. The recent ASGE position 
statement [30] supports AAC targeted-biopsy in expert hands but our data shows that those with 
training can achieve the same thresholds as experts with our image and video-based assessments. 
 
Training modules on lesion recognition and in-vivo diagnosis have traditionally relied on static 
images. In real-life, assessments are made on dynamic and moving images. Therefore, assessment 
and training of endoscopists in AAC-assisted lesion recognition, would in theory, be better 
performed using video-clips, that more closely reflect real-time practice. Our data, however, show 
no significant difference in performance when endoscopists are assessed using images or videos.  
 
 There are some limitations to this study. We don’t know whether success in this training module 
using images and videos, translates to success in real-life cases. We hope to answer this question 
following the completion of our randomised, crossover, tandem endoscopy study comparing Seattle 
protocol and AA-targeted biopsy in Barrett’s surveillance (The ABBA Study)[31]. Our construct 
validity data showed that experts in this field had high sensitivity (95-100%) and high NPV (95-
100%). At the end of training, even non-expert, AAC naïve endoscopists were able to achieve 
sensitivity and specificity within expert range. We believe this important finding demonstrates the 
strength of our training pathway. We are unable to answer the question as to whether performance 
drops off with time as there were only 2 weeks between completion of the online training module 
and the interactive seminar. Another limitation is that the images and videos selected did not 
include low grade dysplasia, endoscopic recognition of low grade dysplasia is challenging but an 
important entity given the recent evidence for ablation of low grade dysplasia[32].  
 
This study has a robust design with a well-validated library of images and videos where the 
performance of the library was validated prior to its use. This study proves the effectiveness of an 
online training module for AAC and demonstrates the added clinical value of an interactive training 
day incorporating expert endoscopists and live cases. 
 
 
Conclusions 
 
Acetic acid chromoendoscopy is a readily available and cheap technology that has the potential to 
improve Barrett’s surveillance and neoplasia yield. This study suggests that the technique can be 
taught effectively through a simple and easy to implement training module that could be rolled out 
on a larger scale. We have demonstrated that the tool has good construct and validity and is 
universally applicable for endoscopists of all backgrounds, but favours those with limited or no 
acetic acid experience. 
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 Job title Years 
Experience 
No of OGD’s No of Barrett’s Number of AAC 
1. Cons GI Physician 33 10,000 1500 200 
2. Cons GI Physician 13 6,500 1,000 225 
3. Cons GI Physician 15 10,000 1,250 300 
4. Cons GI Physician 15 8,000 700 100 
5. Cons GI Physician 17 5,000 880 60 
6. Cons GI Surgeon 45 17,000 4,000 0 
7. Cons GI Surgeon 18 7,000 2,000 0 
8. Nurse Endoscopist 12 8000 3,000 0 
9. Nurse Endoscopist 7 8,400 1,680 288 
10. Nurse Endoscopist 4 2496 381 1 
11. Nurse Endoscopist 2 695 76 4 
12. Nurse Endoscopist 9 9,000 1,000 1 
13. Nurse Endoscopist 12 15,000 1,500 1 
Table 1: Experience and Background of endoscopists enrolled in the study 
 
Group Accuracy Sensitivity  Specificity PPV NPV Kappa 
Experts n=2 96% 
(0.88-0.96) 
100% 
(0.92-1.0) 
93% 
(0.85-0.93) 
93% 
(0.85-0.93) 
100% 
(0.91-1.0) 
0.80 
Novices n=3 73% 
(0.63-0.80) 
72% 
(0.62-0.80) 
73% 
(0.64-0.81) 
71% 
(0.61-0.79) 
74% 
(0.65-0.82) 
0.30 
P-Value 
 
=0.009 =0.096 =0.313 =0.111 =0.019  
Table 2a: Validation of the test module (95% Confidence Interval) showing significant difference in 
performance between experts and novices when assessed with still-images. 
  
  
Table 2b: Validation of the test module (95% Confidence Interval) showing significant difference in 
performance between experts and novices when assessed with dynamic videos. 
 
 
 Accuracy Sensitivity  Specificity PPV NPV Kappa 
Baseline 79% 
0.75-0.83 
83% 
0.79-0.86 
76% 
0.73-0.79 
76% 
0.72-0.79 
83% 
0.79-0.86 
0.48 
Post-Online 
Training 
86% 
0.83-0.88 
95% 
0.92-0.97 
79% 
0.76-0.81 
80% 
0.78-0.82 
94% 
0.91-0.98 
0.67 
P-value <0.01 <0.01 =0.522 =0.459 <0.01  
Table 3a: Baseline assessment vs post online training assessment (95% Confidence Interval) Images, 
significant improvement in accuracy, sensitivity and negative predictive value. 
 
 Accuracy Sensitivity  Specificity PPV NPV Kappa 
Baseline 78% 
0.72-0.83 
73% 
0.67-0.78 
83% 
0.77-0.88 
81% 
0.75-0.87 
76% 
0.70-0.80 
0.41 
Post-Online 
Training 
82% 
0.77-0.86 
91% 
0.86-0.95 
74%  
0.69-0.78 
78% 
0.73-0.81 
89% 
0.83-0.94 
0.51 
P-value =0.281 =0.011 =0.194 =0.505 =0.041  
Table 3b: Baseline assessment vs post online training assessment (95% Confidence Interval) Videos, 
significant improvement in sensitivity and negative predictive value. 
 
 Accuracy Sensitivity  Specificity PPV NPV Kappa 
Post-Online 
Training 
86% 
0.83-0.88 
95% 
0.92-0.97 
79% 
0.76-0.81 
80% 
0.78-0.82 
94% 
0.91-0.98 
0.67 
Interactive 
Seminar 
82% 
0.80-0.84 
98% 
0.95-0.99 
68% 
0.66-0.69 
74% 
0.72-0.75 
97% 
0.94-0.99 
0.75 
P-value =0.028 =0.084 =0.007 =0.002 =0.131  
Table 4a: Post-online training assessment vs Interactive training day (95% Confidence Interval) 
Images. Improvements in sensitivity and NPV. 
 
 
Group Accuracy Sensitivity  Specificity PPV NPV Kappa 
Experts n=2 97.50% 
(0.84-0.98) 
95% 
(0.81-0.95) 
100% 
(0.86-1.0) 
100% 
(0.85-1.0) 
95% 
(0.82-0.95) 
0.9 
Novices n=3 77% 
(0.63-0.87) 
77% 
(0.63-0.87) 
77% 
(0.63-0.87) 
77% 
(0.63-0.87) 
77% 
(0.63-0.87) 
0.40 
P-value 
 
=0.021 =0.408 =0.133 =0.018 =0.382  
  Accuracy Sensitivity  Specificity PPV NPV Kappa 
Post-Online 
Training 
82% 
0.77-0.86 
91% 
0.86-0.95 
74%  
0.69-0.78 
78% 
0.73-0.81 
89% 
0.83-0.94 
0.51 
Interactive 
Seminar 
79% 
0.75-0.81 
99%  
0.95-1.0 
60% 
0.56-0.61 
71% 
0.68-0.72 
98% 
0.91-1.0 
0.63 
P-value =0.322 =0.003 =0.005 =0.035 =0.004  
Table 4b: Post online training assessment vs Interactive training day (95% Confidence Interval) 
Videos demonstrating statistically significant improvement in sensitivity and negative predictive 
value. 
 
 Accuracy Sensitivity  Specificity PPV NPV 
Pre-training 
Images 
79% 
0.75-0.83 
83% 
0.79-0.86 
76% 
0.73-0.79 
76% 
0.72-0.79 
83% 
0.79-0.86 
Pre-training 
Videos 
78% 
0.72-0.83 
73% 
0.67-0.78 
83% 
0.77-0.88 
81% 
0.75-0.87 
76%* 
0.70-0.80 
 
Post-Online 
Training 
Images 
86% 
0.83-0.88 
95% 
0.92-0.97 
79% 
0.76-0.81 
80% 
0.78-0.82 
94% 
0.91-0.98 
Post-Online 
Training 
Videos 
82% 
0.77-0.86 
91% 
0.86-0.95 
74%  
0.69-0.78 
78% 
0.73-0.81 
89% 
0.83-0.94 
 
Post-Seminar 
Images 
82% 
0.80-0.84 
98% 
0.95-0.99 
68% 
0.66-0.69 
74% 
0.72-0.75 
97% 
0.94-0.99 
Post-Seminar 
Videos 
79%* 
0.75-0.81 
99%  
0.95-1.0 
60%* 
0.56-0.61 
71% 
0.68-0.72 
98% 
0.91-1.0 
Table 5: Comparison of images and videos for each stage of training. (*p<0.05) 
 
 Accuracy Sensitivity Specificity PPV NPV 
 Naïve User Naïve User Naïve User Naïve User Naïve User 
Pre-Training 78% 81% 71% 95% 83% 68% 81% 74% 77% 94% 
Post-Online 85%* 88%* 92%* 97% 78% 79%* 80% 81%* 93%* 97% 
Interactive 
Seminar 
83% 82% 97% 99% 70% 66% 75% 72% 97% 99% 
Table 6a Subgroup analysis of performance naïve vs users – Images (*p<0.05) 
 
 
 Accuracy Sensitivity Specificity PPV NPV 
 Naïve User Naïve User Naïve User Naïve User Naïve User 
Pre-Training 71% 83% 59% 84% 84% 81% 83% 82% 67% 87% 
Post-Online 82% 83% 90%* 92% 74% 76% 80% 80% 89%* 89% 
Interactive 
Seminar 
81% 78% 99%* 98%* 63% 57% 73% 71% 98% 98%* 
Table 6b Subgroup analysis of performance naïve vs users – Videos (*p<0.05) 
  
Figure 1a: Non-dysplastic Barrett’s Mucosa 
Figure 1b: The same patient following AAC 
 
  
Figure 2a: Area of dysplastic Barrett’s with high-definition white light 
Figure 2b: AAC- assisted lesion recognition – area of dysplasia highlighted by early loss of 
acetowhitening 
  
  
 
 
Figure 3: Example screenshot of online training module 
 
 
Figure 4: Flow diagram of training and assessment 
 
 
Post-workshop assessment
INTERVENTION 2: Live interactive workshop
Post-online training assessment
INTERVENTION 1: Online Training Module
Pre-training assessment
